Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Polizzotto Website

Mark N. Polizzotto, M.B., B.S., B.Med.Sc

Selected Publications

1)  Shahbazi S, Peer CJ, Polizzotto MN, Uldrick TS, Roth J, Wyvill KM, Aleman K, Zeldis JB, Yarchoan R, Figg WD.
A sensitive and robust HPLC assay with fluorescence detection for the quantification of pomalidomide in human plasma for pharmacokinetic analyses.
J Pharm Biomed Anal. 92: 63-8, 2014.
2)  Polizzotto MN, Uldrick TS, Yarchoan R.
Case 29-2013: An HIV-positive man with dyspnea and skin lesions.
N. Engl. J. Med. 370: 87-8, 2014.
3)  Labo N, Miley W, Marshall V, Gillette W, Esposito D, Bess M, Turano A, Uldrick T, Polizzotto MN, Wyvill KM, Bagni R, Yarchoan R, Whitby D.
Heterogeneity and breadth of host antibody response to KSHV infection demonstrated by systematic analysis of the KSHV proteome.
PLoS Pathog. 10: e1004046, 2014.
4)  McQuilten ZK, Wood EM, Polizzotto MN, Campbell LJ, Wall M, Curtis DJ, Farrugia H, McNeil JJ, Sundararajan V.
Underestimation of myelodysplastic syndrome incidence by cancer registries: Results from a population-based data linkage study.
Cancer. [Epub ahead of print], 2014.
5)  Kainerstorfer JM, Polizzotto MN, Uldrick TS, Rahman R, Hassan M, Najafizadeh L, Ardeshirpour Y, Wyvill KM, Aleman K, Smith PD, Yarchoan R, Gandjbakhche AH.
Evaluation of non-invasive multispectral imaging as a tool for measuring the effect of systemic therapy in Kaposi sarcoma.
PLoS ONE. 8: e83887, 2013.
6)  Polizzotto MN, Uldrick TS, Wang V, Aleman K, Wyvill KM, Marshall V, Pittaluga S, O'Mahony D, Whitby D, Tosato G, Steinberg SM, Little RF, Yarchoan R.
Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease.
Blood. 122: 4189-98, 2013.
7)  McQuilten ZK, Polizzotto MN, Wood EM, Sundararajan V.
Myelodysplastic syndrome incidence, transfusion dependence, health care use, and complications: an Australian population-based study 1998 to 2008.
Transfusion. 53: 1714-21, 2013.
8)  Polizzotto MN, Uldrick TS, Hu D, Yarchoan R.
Clinical Manifestations of Kaposi Sarcoma Herpesvirus Lytic Activation: Multicentric Castleman Disease (KSHV-MCD) and the KSHV Inflammatory Cytokine Syndrome.
Front Microbiol. 3: 73, 2012.
9)  Gasperini P, Espigol-Frigole G, McCormick PJ, Salvucci O, Maric D, Uldrick TS, Polizzotto MN, Yarchoan R, Tosato G.
Kaposi sarcoma herpesvirus promotes endothelial-to-mesenchymal transition through Notch-dependent signaling.
Cancer Res. 72: 1157-69, 2012.
10)  Uldrick TS, Wyvill KM, Kumar P, O'Mahony D, Bernstein W, Aleman K, Polizzotto MN, Steinberg SM, Pittaluga S, Marshall V, Whitby D, Little RF, Yarchoan R.
Phase II Study of Bevacizumab in Patients With HIV-Associated Kaposi's Sarcoma Receiving Antiretroviral Therapy.
J. Clin. Oncol. 30: 1476-83, 2012.
11)  Uldrick TS, Polizzotto MN, Yarchoan R.
Recent advances in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease.
Curr Opin Oncol. 24: 495-505, 2012.
12)  Ray A, Marshall V, Uldrick T, Leighty R, Labo N, Wyvill K, Aleman K, Polizzotto MN, Little RF, Yarchoan R, Whitby D.
Sequence Analysis of Kaposi Sarcoma-Associated Herpesvirus (KSHV) MicroRNAs in Patients with Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome.
J. Infect. Dis. 205: 1665-76, 2012.
13)  Uldrick TS, Polizzotto MN, Aleman K, O'Mahony D, Wyvill KM, Wang V, Marshall V, Pittaluga S, Steinberg SM, Tosato G, Whitby D, Little RF, Yarchoan R.
High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy.
Blood. 117: 6977-86, 2011.
14)  McQuilten ZK, Schembri N, Polizzotto MN, Akers C, Wills M, Cole-Sinclair MF, Whitehead S, Wood EM, Phillips LE.
Hospital blood bank information systems accurately reflect patient transfusion: results of a validation study.
Transfusion. 51: 943-8, 2011.
15)  Polizzotto MN, Skinner M, Cole-Sinclair MF, Opat SS, Spencer A, Avery S.
Allo-SCT for hematological malignancies in the setting of HIV.
Bone Marrow Transplant. 45: 584-6, 2010.
16)  Polizzotto MN, Jones P, Cameron PU, Spelman D, Woolley IJ.
The influence of splenectomy on the infectious complications and outcomes of people with HIV: marked, sustained elevation in risk of severe infection with bacteria including Streptococcus pneumoniae.
J. Acquir. Immune Defic. Syndr. 55: e24-6, 2010.
17)  Shortt J, Polizzotto MN, Waters N, Borosak M, Moran M, Comande M, Devine A, Jolley DJ, Wood EM.
Assessment of the urgency and deferability of transfusion to inform emergency blood planning and triage: the Bloodhound prospective audit of red blood cell use.
Transfusion. 49: 2296-303, 2009.
18)  Polizzotto MN, McComish JS, Dawson MA, Opat SS, Cole-Sinclair MF.
Burkitt lymphoma in the setting of common variable immunodeficiency.
Ann. Hematol. 88: 819-20, 2009.
19)  Polizzotto MN, Phillips LE, Cannell P, Cohney S, Davies C, Opat SS, McNeil JJ, Wood EM.
The thrombotic thrombocytopenic purpura registry: a new national resource to inform patient care and medical research.
Intern Med J. 39: 72-3, 2009.
20)  Shortt J, Westall GP, Roxby D, Chen JW, Snell GI, Polizzotto MN, Magrin G, Webb A, Street AM, Borosak M, Wood EM, Cole-Sinclair MF.
A 'dangerous' group O donor: severe hemolysis in all recipients of organs from a donor with multiple red cell alloantibodies.
Am. J. Transplant. 8: 711-4, 2008.
21)  Polizzotto MN, Shortt J, Opat SS, Cole-Sinclair MF.
A drop of vitriol: microspherocytosis following sulphuric acid exposure.
Br. J. Haematol. 140: 596, 2008.
22)  Polizzotto MN, Shortt J, Cole-Sinclair MF.
Acute splenic sequestration complicating sickle cell disease.
Eur. J. Haematol. 81: 81, 2008.
23)  Shortt J, Polizzotto MN, Opat SS, Cole-Sinclair MF.
Oxidative haemolysis due to 'poppers'.
Br. J. Haematol. 142: 328, 2008.
24)  Polizzotto MN, Wood EM, Ingham H, Keller AJ.
Reducing the risk of transfusion-transmissible viral infection through blood donor selection: the Australian experience 2000 through 2006.
Transfusion. 48: 55-63, 2008.
25)  Polizzotto MN, Neo H, Spelman D, Shortt J, Cole-Sinclair MF, Borosak M, Wong P, Wood EM.
Streptococcus pneumoniae septicemia associated with red blood cell transfusion.
Transfusion. 48: 1520-1, 2008.
26)  Dawson MA, Avery S, McQuilten ZK, Bailey MJ, Shortt J, Polizzotto MN, Wood EM, Cole-Sinclair MF.
Blood transfusion requirements for patients undergoing chemotherapy for acute myeloid leukemia how much is enough?.
Haematologica. 92: 996-7, 2007.
27)  Polizzotto MN, Saw MM, Tjhung I, Chua EH, Stockwell TR.
Fluid skills: drinking games and alcohol consumption among Australian university students.
Drug Alcohol Rev. 26: 469-75, 2007.
28)  Polizzotto MN, Whelan G.
Hepatitis B immunity in a population of drug and alcohol users.
Drug Alcohol Rev. 26: 417-9, 2007.
29)  Polizzotto MN, Street AM, Wright E.
The safety and efficacy of enfuvirtide therapy for HIV infection in patients with hemophilia: a case series.
Clin. Infect. Dis. 45: e39-41, 2007.
30)  Polizzotto MN, Cousins V, Schwarer AP.
Bisphosphonate-associated osteonecrosis of the auditory canal.
Br. J. Haematol. 132: 114, 2006.
31)  Polizzotto MN, Martin P.
Buried alive: an unusual problem at the end of life.
J Palliat Care. 22: 117-8, 2006.
32)  Polizzotto MN, Gibbs SD, Beswick W, Seymour JF.
Cardiac involvement in Henoch-Schonlein purpura.
Intern Med J. 36: 328-31, 2006.
33)  Dawson MA, Polizzotto MN, Gordon A, Roberts SK, Spencer A.
Extramedullary relapse of multiple myeloma presenting as hematemesis and melena.
Nat Clin Pract Oncol. 3: 223-6; quiz 227, 2006.
34)  Polizzotto MN, Bryan T, Ashby MA, Martin P.
Symptomatic management of calciphylaxis: a case series and review of the literature.
J Pain Symptom Manage. 32: 186-90, 2006.
35)  Polizzotto MN, Tam CS, Milner A, Januszewicz EH, Prince HM, Westerman D, Wolf MM, Seymour JF.
The influence of increasing age on the deliverability and toxicity of fludarabine-based combination chemotherapy regimens in patients with indolent lymphoproliferative disorders.
Cancer. 107: 773-80, 2006.
36)  Polizzotto MN, Dawson MA, Opat SS.
Failure of rituximab monotherapy in lymphomatoid granulomatosis.
Eur. J. Haematol. 75: 172-3, 2005.
37)  Polizzotto MN, Bartlett PF, Turnley AM.
Expression of "suppressor of cytokine signalling" (SOCS) genes in the developing and adult mouse nervous system.
J. Comp. Neurol. 423: 348-58, 2000.
38)  Dottori M, Hartley L, Galea M, Paxinos G, Polizzotto M, Kilpatrick T, Bartlett PF, Murphy M, Köntgen F, Boyd AW.
EphA4 (Sek1) receptor tyrosine kinase is required for the development of the corticospinal tract.
Proc. Natl. Acad. Sci. U.S.A. 95: 13248-53, 1998.
Click Here to View Collapsed Bibliography.

This page was last updated on 5/15/2014.